<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554448</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-1</org_study_id>
    <nct_id>NCT02554448</nct_id>
  </id_info>
  <brief_title>Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy</brief_title>
  <official_title>Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the value of dynamic change in detecting CTCs in
      peripheral blood from stage III rectal cancer patients undergoing neoadjuvant Folfox
      treatment and chemoradiotherapy,before and after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time
      biopsy' of tumor biological activity. Enumeration of CTCs in rectal cancer patients could
      play an important role in diagnosis, predicting the risk for tumor recurrence and
      effectiveness of neoadjuvant therapy.

      The investigators choose several timepoints to detect the dynamic change of CTCs,1 day before
      the 1st ,3rd and 5th(if the patient needs before surgery) neoadjuvant therapy course,1 day
      before and 7days ,3 month,6 month after surgery. Approximately 7.5-mL ethylene diamine
      tetraacetic acid(EDTA)-blood was drawn by vein puncture from patients with rectal cancer .
      Briefly, the number of CTCs will be count by the cellsearch system , recorded and analysed by
      the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of Circulating Tumor Cells (CTCs)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rectal Neoplasms</condition>
  <condition>Circulating Tumor Cells</condition>
  <arm_group>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use ISET system to test the number of CTCs from patients before and during treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ISET system</intervention_name>
    <description>Use ISET system to test the number of CTCs from patients before and during treatment.</description>
    <arm_group_label>Circulating Tumor Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: &gt;18 years old.

          2. Diagnosis of stage III rectal cancer based on histology.

          3. Will receive neoadjuvant treatment using Folfox or chemoradiotherapy .

          4. Life expectancy: Greater than 3 months.

          5. Patients have no severe inflammation, such as vasculitis.

          6. Ability to understand the study protocol and a willingness to sign a written informed
             consent document

        Exclusion Criteria:

          1. Patients with other primary tumor except rectal cancer.

          2. History of coagulation disorders or anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanxin Luo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanxin Luo, PhD</last_name>
    <phone>+86-13826190263</phone>
    <email>luoyx25@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weida Lin, master</last_name>
    <phone>+86-13430354015</phone>
    <email>linweida529@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliate Hospital of Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanxin Luo, PhD</last_name>
      <phone>+86-13826190263</phone>
      <email>luoyx25@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weida Lin, master</last_name>
      <phone>+86-13430354015</phone>
      <email>linweida529@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>May 28, 2016</last_update_submitted>
  <last_update_submitted_qc>May 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>rectal Neoplasms</keyword>
  <keyword>neoadjuvant otherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not ready to share the data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

